Overview

Gender

male

Investor Type

Investment Partner

Brad Bolzon is both a Menlo Park and Basel, Switzerland-based Managing Director.Brad brings more than thirteen years of global pharmaceutical industry experience to Versant’s biotech investment team. He specializes in early-stage biotech investing with a particular emphasis on new company start-ups.Prior to joining Versant, Brad served as Executive Vice President, Global Head of Business Development, Licensing & Alliances with F. Hoffmann-La Roche. Under his leadership, Roche established alliances with over 75 biotech companies worldwide and significantly strengthened its product pipeline.Previously, Brad held executive roles at Eli Lilly in drug discovery, clinical research, regulatory affairs, and business development.

CURRENT BOARD SEATS:Anaphore, FLAP, Flexion, Inception, Panmira, Quanticel,
EuroVentures, a wholly-owned start-up incubator of Versant Ventures.PREVIOUS BOARD INVOLVEMENT:Amira (acquired), BioTie, Metabolex, Okairos (acquired),
Speedel (acquired), Synosia (acquired).He was learned MS for University of Toronto,and PhD for University of Toronto,Ottawa Heart Institute, post-doctoral research.